Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV.

This study of SARS-CoV-2 mRNA vaccination in 14 persons with HIV demonstrated uniformly high anti-SARS-CoV-2 receptor binding domain antibody titers after two doses, despite varied titers after a single dose. The majority of vaccine reactions were mild and no adverse events occurred.